参考文献: [1]C. Garcia Duran, H. Domenech, G. Villacampa Javierre, et al. Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelia...
HRD testing (determined by BRCAm and genomic instability score) identifies advanced ovarian cancer (AOC) patients who will benefit most from PARPi treatment. The value of these tests
library("scarHRD") scar_score("/pathto/test1.small.seqz.gz",reference = "grch38", seqz=TRUE) Tips 1)reference可以是“grch38”或者“grch37” 2)如果你的比对参考序列是“1”、“2”,“3”这种格式,记得处理一下small.seqz.gz文件,把染色体ID改成“chr1”、“chr2”、“chr3”,这种格式,否...
We herein provide a new comprehensive approach to test HR-status, which aims to assess HRD in a qualitative and quantitative manner. Methods: In addition to a 153-gene NGS panel, quantitative HRD was assessed in a "real-life" collective of 108 "high-grade", stage III/IV ovarian cancer ...
The proportion of patients with positive HRD status was 64.4%.Such results reveal that, compared to Western population, a higher proportion of Chinese ovarian cancer patients benefit from PARP inhibitor maintenance therapy. Figure 1: Distribution of BRCA1 and BRC...
目前,用于HRD检测的产品,经过临床验证且获FDA批准的只有两个,Myriad Genetics myChoice Test和FoundationOne CDx(FDA批准用于检测gLOH),然而Myriad Genetics myChoice Test在国内尚不可及。 F1CDx可以检测卵巢癌患者的HRD状态,HRD阳性定义为合并BRCA1/2突变和/或LOH评分高(≥16%),采用F1CDx检测HRD阳性的判读方法如下...
此外,人群数据的分析显示在806名受试者中HRD阳性(PALOLA-1使用的是 Myriad公司的基因瘢痕检测试剂盒My Choice HRD test,HRD积分大于42认为是HRD阳性)的患者有387例(占总人群48%),其中组织BRCA1/2为突变(tBRCAm)的患者有235例(占总人群29%),HRD阳性的非组织BRCA1/2突变(non-tBRCAm)的患者有152例(占总人群...
2、The test panel covers all coding regions of BRCA1/2 gene, providing dosing guidance for the application of PARP inhibitors olaparib and rucaparib in breast and ovarian cancers. 3, including PIK3CA gene test, providing dosing guidance for breast cancer targeted drug Alpelisib. ...
Conversations about HRD testing with patients should start immediately after an advanced ovarian cancer diagnosis.4,7Completing this step is critical, even if a patient has already had a biomarker test. Why? Because even without a breast cancer gene mutation (BRCAm), you can stil...
Exploratory HRD and PD-L1 analysis of L-MOCA Study: Olaparib Maintenance Monotherapy in Asian Patients with Platinum Sensitive Relapsed Ovarian Cancer. L-MOCA研究:奥拉帕利单药维持治疗在亚洲铂敏感复发卵巢癌患者中的HRD和PD-L1...